NMS · Analyst Forecast

Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast & Price Target

$2.72 NMS: RXRX Market Cap $1.69B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 13, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Recursion Pharmaceuticals, Inc. (RXRX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Recursion Pharmaceuticals, Inc., analysts forecast revenue rising from $70.75M in 2024 to $247.50M in 2029; the average estimate for 2029 earnings per share is −$0.94; with published estimates ranging from −$1.69 to −$0.34; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$2.72
Consensus targetThe average of the price targets analysts have published.$5.90
Median targetThe middle target, less affected by a single outlier.$5.90
Highest targetThe most optimistic published target.$5.90
Lowest targetThe most pessimistic published target.$5.90
Difference from priceHow far the consensus target sits from today’s price.+116.9%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2024$63.61M$70.75M$85.45M6
2025$46.03M$61.52M$81.40M6
2026$28.99M$38.95M$58.98M6
2027$17.82M$43.95M$74.09M6
2028$9.90M$38.20M$69.27M5
2029$126.20M$247.50M$400.11M2

Earnings per share forecast

YearLowAverageHighAnalysts
2024−$1.63−$1.54−$1.456
2025−$1.66−$1.57−$1.466
2026−$0.92−$0.88−$0.866
2027−$0.95−$0.83−$0.676
2028−$0.80−$0.76−$0.735
2029−$1.69−$0.94−$0.342

Recursion Pharmaceuticals, Inc. (RXRX) forecast — frequently asked questions

What is the analyst price target for Recursion Pharmaceuticals, Inc.?

Analysts covering Recursion Pharmaceuticals, Inc. (RXRX) have a consensus price target of $5.90, 116.9% above the current price of $2.72. Published targets range from $5.90 to $5.90. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Recursion Pharmaceuticals, Inc.'s earnings?

The average analyst estimate for Recursion Pharmaceuticals, Inc. (RXRX) earnings per share in 2029 is -0.94, with individual estimates between -1.69 and -0.34.

How much revenue is Recursion Pharmaceuticals, Inc. expected to make?

Analysts forecast Recursion Pharmaceuticals, Inc. (RXRX) revenue of $247.50M in 2029, based on 2 published estimates.

How many analysts cover RXRX?

6 analysts contribute estimates for Recursion Pharmaceuticals, Inc. (RXRX). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.